PT1313703E - Precursores de fármacos para ligandos de receptores de nmda - Google Patents

Precursores de fármacos para ligandos de receptores de nmda Download PDF

Info

Publication number
PT1313703E
PT1313703E PT01965201T PT01965201T PT1313703E PT 1313703 E PT1313703 E PT 1313703E PT 01965201 T PT01965201 T PT 01965201T PT 01965201 T PT01965201 T PT 01965201T PT 1313703 E PT1313703 E PT 1313703E
Authority
PT
Portugal
Prior art keywords
compound
formula
hydroxy
benzyl
ethanesulfonyl
Prior art date
Application number
PT01965201T
Other languages
English (en)
Portuguese (pt)
Inventor
Emmanuel Pinard
Georg Jaeschke
Bernd Buettelmann
Rene Wyler
Alexander Alanine
Holger Fisher
Marie-Paule Heitz Neidhart
Joerg Huwyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT1313703E publication Critical patent/PT1313703E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT01965201T 2000-08-21 2001-08-20 Precursores de fármacos para ligandos de receptores de nmda PT1313703E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
PT1313703E true PT1313703E (pt) 2008-03-25

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01965201T PT1313703E (pt) 2000-08-21 2001-08-20 Precursores de fármacos para ligandos de receptores de nmda

Country Status (35)

Country Link
US (1) US6407235B1 (cg-RX-API-DMAC7.html)
EP (1) EP1313703B1 (cg-RX-API-DMAC7.html)
JP (1) JP4162991B2 (cg-RX-API-DMAC7.html)
KR (1) KR100589991B1 (cg-RX-API-DMAC7.html)
CN (1) CN1227230C (cg-RX-API-DMAC7.html)
AR (1) AR030373A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386022T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001285894B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113348A (cg-RX-API-DMAC7.html)
CA (1) CA2419279C (cg-RX-API-DMAC7.html)
CY (1) CY1107937T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303319B6 (cg-RX-API-DMAC7.html)
DE (1) DE60132782T2 (cg-RX-API-DMAC7.html)
DK (1) DK1313703T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034489A (cg-RX-API-DMAC7.html)
EG (1) EG24293A (cg-RX-API-DMAC7.html)
ES (1) ES2299508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030125B1 (cg-RX-API-DMAC7.html)
HU (1) HU229802B1 (cg-RX-API-DMAC7.html)
IL (1) IL154254A0 (cg-RX-API-DMAC7.html)
JO (1) JO2289B1 (cg-RX-API-DMAC7.html)
MA (1) MA26947A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001311A (cg-RX-API-DMAC7.html)
MY (1) MY136065A (cg-RX-API-DMAC7.html)
NO (1) NO324941B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523990A (cg-RX-API-DMAC7.html)
PA (1) PA8525601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020291A1 (cg-RX-API-DMAC7.html)
PL (1) PL204215B1 (cg-RX-API-DMAC7.html)
PT (1) PT1313703E (cg-RX-API-DMAC7.html)
RS (1) RS51467B (cg-RX-API-DMAC7.html)
RU (1) RU2272027C2 (cg-RX-API-DMAC7.html)
SI (1) SI1313703T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002016321A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300894B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CA2419279C (en) 2008-10-14
HUP0301548A3 (en) 2010-03-29
EP1313703A1 (en) 2003-05-28
JO2289B1 (en) 2005-09-12
NO324941B1 (no) 2008-01-07
KR20030022417A (ko) 2003-03-15
CA2419279A1 (en) 2002-02-28
SI1313703T1 (sl) 2008-06-30
RU2272027C2 (ru) 2006-03-20
DE60132782T2 (de) 2009-02-05
PE20020291A1 (es) 2002-04-17
KR100589991B1 (ko) 2006-06-15
EP1313703B1 (en) 2008-02-13
CZ303319B6 (cs) 2012-08-01
YU13003A (sh) 2006-05-25
JP4162991B2 (ja) 2008-10-08
NZ523990A (en) 2004-09-24
PL361387A1 (en) 2004-10-04
CN1447793A (zh) 2003-10-08
AU2001285894B2 (en) 2006-06-15
HRP20030125A2 (en) 2005-02-28
BR0113348A (pt) 2003-07-08
US6407235B1 (en) 2002-06-18
ZA200300894B (en) 2004-04-30
JP2004506715A (ja) 2004-03-04
CN1227230C (zh) 2005-11-16
AR030373A1 (es) 2003-08-20
MA26947A1 (fr) 2004-12-20
AU8589401A (en) 2002-03-04
HK1059083A1 (en) 2004-06-18
DK1313703T3 (da) 2008-05-19
PL204215B1 (pl) 2009-12-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
NO20030781D0 (no) 2003-02-19
CZ2003492A3 (cs) 2004-01-14
ES2299508T3 (es) 2008-06-01
MXPA03001311A (es) 2003-06-30
WO2002016321A1 (en) 2002-02-28
PA8525601A1 (es) 2002-04-25
HUP0301548A2 (hu) 2003-08-28
NO20030781L (no) 2003-02-19
DE60132782D1 (de) 2008-03-27
CY1107937T1 (el) 2013-09-04
US20020040037A1 (en) 2002-04-04
ATE386022T1 (de) 2008-03-15
MY136065A (en) 2008-08-29
HU229802B1 (hu) 2014-07-28
IL154254A0 (en) 2003-09-17
HRP20030125B1 (en) 2011-07-31
ECSP034489A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
US6737425B1 (en) N,N-substituted cyclic amine derivatives
BR112020011953A2 (pt) ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa
MX2013001494A (es) Promotores de apoptosis de n-acilsulfonamida.
BR112015021985B1 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
SE452615B (sv) Piperazinderivat och forfaranden for framstellning derav
EP1276729B1 (en) New neurokinin antagonists for use as medicaments
EP4482579B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
CN101720316A (zh) 新肽去甲酰基酶抑制剂化合物及其制备方法
JP2010536927A (ja) 新種のヒストンデアセチラーゼ阻害剤
AU2001285894B2 (en) Prodrugs to NMDA receptor ligands
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
ES2230685T3 (es) Quinoxalinadionas.
PT93515B (pt) Processo para a preparacao de novas benzotiopiranilaminas
EP1368032B1 (en) Excitatory amino acid receptor antagonists
WO2019094689A1 (en) Caffeic acid derivatives for treating hyperproliferative diseases
CN120518506A (zh) 基于给电子效应改性的卡巴拉汀衍生物及其制备方法和应用
JP2013500320A (ja) 2−アミノ−2−フェニル−アルカノールの誘導体、その製造、及びこれを含有する医薬組成物
BR112019018879A2 (pt) inibidores duplos de magl e faah
JPH068267B2 (ja) N,n−二置換フエニルセリン誘導体及びそれを有効成分とする中枢神経系用剤